Pinnacle Biologics Announces Marketing and Distribution Agreement With MedImmune.
PR Newswire Europe, February, 2008
ROCKVILLE, Maryland, February 19 /PRNewswire/ --
Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company, today announced it has entered into an exclusive distribution agreement with MedImmune for Ethyol(R) (amifostine). The agreement, which is scheduled to take effect on June 1, 2008, grants Pinnacle Biologics exclusive Ethyol marketing authorization, certain licenses and distribution rights in Western Europe, Turkey and Israel. Additional terms of the agreement were not disclosed.
"The agreement with MedImmune represents the first step in Pinnacle's growth as well as provides the opportunity to showcase our vast capability to assist large pharmaceutical and biotechnology companies in optimizing the international...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- LIFO vs. FIFO: a return to the basics
